Analysts’ Weekly Ratings Changes for Kura Oncology (KURA)

A number of firms have modified their ratings and price targets on shares of Kura Oncology (NASDAQ: KURA) recently:

• 8/12/2024 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.
• 8/12/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 8/9/2024 – Kura Oncology had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 8/9/2024 – Kura Oncology had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
• 8/9/2024 – Kura Oncology had its price target lowered by analysts at Stifel Nicolaus from $28.00 to $26.00. They now have a “buy” rating on the stock.
• 6/24/2024 – Kura Oncology had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
• 6/18/2024 – Kura Oncology had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.

Kura Oncology Stock Performance

Shares of NASDAQ KURA traded up $0.01 during midday trading on Wednesday, reaching $19.04. 277,406 shares of the company traded hands, compared to its average volume of 1,036,451. The stock has a 50-day moving average price of $20.60 and a 200 day moving average price of $20.69. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -8.77 and a beta of 0.88. Kura Oncology, Inc. has a 52 week low of $7.41 and a 52 week high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.67 and a quick ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. Kura Oncology’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.53) earnings per share. Sell-side analysts anticipate that Kura Oncology, Inc. will post -2.56 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other news, insider Teresa Brophy Bair sold 2,615 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the completion of the transaction, the insider now directly owns 68,979 shares in the company, valued at $1,527,884.85. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC grew its holdings in Kura Oncology by 40.4% during the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after acquiring an additional 1,449 shares during the period. SG Americas Securities LLC bought a new position in shares of Kura Oncology during the 1st quarter worth approximately $110,000. Cape Investment Advisory Inc. acquired a new position in shares of Kura Oncology in the fourth quarter valued at $176,000. Saxon Interests Inc. acquired a new position in Kura Oncology in the 1st quarter valued at about $201,000. Finally, Entropy Technologies LP bought a new position in shares of Kura Oncology during the first quarter worth approximately $218,000.

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.